GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Sold by Kimelman & Baird LLC

Kimelman & Baird LLC lowered its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 44.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,012 shares of the company’s stock after selling 808 shares during the period. Kimelman & Baird LLC’s holdings in GE HealthCare Technologies were worth $79,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Darwin Wealth Management LLC acquired a new stake in shares of GE HealthCare Technologies in the third quarter worth $31,000. Continuum Advisory LLC boosted its stake in shares of GE HealthCare Technologies by 101.8% in the third quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock valued at $31,000 after purchasing an additional 168 shares during the period. Bank of Jackson Hole Trust purchased a new position in shares of GE HealthCare Technologies in the fourth quarter valued at $32,000. OFI Invest Asset Management purchased a new position in shares of GE HealthCare Technologies in the fourth quarter valued at $34,000. Finally, Avion Wealth boosted its stake in shares of GE HealthCare Technologies by 497.4% in the fourth quarter. Avion Wealth now owns 460 shares of the company’s stock valued at $35,000 after purchasing an additional 383 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

GE HealthCare Technologies Price Performance

Shares of GEHC opened at $81.97 on Monday. The company has a market cap of $37.48 billion, a P/E ratio of 18.93, a PEG ratio of 3.19 and a beta of 1.13. The stock has a fifty day moving average price of $87.26 and a 200 day moving average price of $86.13. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 0.83. GE HealthCare Technologies Inc. has a 12 month low of $74.51 and a 12 month high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.19. The firm had revenue of $5.32 billion during the quarter, compared to the consensus estimate of $5.33 billion. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. On average, research analysts forecast that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on GEHC. Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and upped their target price for the company from $95.00 to $103.00 in a research note on Wednesday, January 8th. The Goldman Sachs Group upgraded shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and upped their target price for the company from $85.00 to $100.00 in a research note on Tuesday, March 11th. Citigroup upped their target price on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Finally, Wells Fargo & Company increased their price objective on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $98.75.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.